CSAM Health Group AS (OMDA.OL) Stock Analysis & AI Equity Report

Medical - Healthcare Information Services NOK Explore free reports

CSAM Health Group AS (OMDA.OL) overview

CSAM Health Group AS (OMDA.OL) stock analysis and AI equity research. For the latest completed financial year, 2022, CSAM Health Group AS reported revenue of NOK 367m and operating profit of NOK -81.9m; the year-end share price was 38.00 NOK and market capitalisation was NOK 797m. CSAM Health Group AS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CSAM Health Group AS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueNOK 28.8mFY 2022
Share price38.00 NOKFY 2022 year end
RevenueNOK 367mFY 2022
Operating profitNOK -81.9mFY 2022
Net earningsNOK -132mFY 2022
Market capitalisationNOK 797mFY 2022 year end

Figures updated on 2025-12-12. Data will be refreshed during report generation.

About CSAM Health Group AS

CSAM Health Group AS, now Omda AS, develops specialised software for healthcare and emergency services. Its products support clinical information management, connected healthcare, maternity and fertility, health analytics, imaging, and emergency workflows. The group serves hospitals and other healthcare providers with tools designed to improve information sharing, operational efficiency, and patient safety.

Generate the CSAM Health Group AS report

CSAM Health Group AS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for CSAM Health Group AS and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.